ArticleInternational journal of clinical oncology2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer.

Noriomi MatsumuraPubMed ↗Publisher ↗

No numbers read from the abstract.